NOVARTIS has been granted
US Food and Drug Administration
(FDA) approval for Zykadia
(ceritinib).
This was the first therapy for
patients with ALK+ non-small cell
lung cancer (NSCLC) previously
treated with the ALK inhibitor
crizotinib, Novartis said.
Zykadia demonstrated an overall
response rate of 54.6% in patients
with ALK+ metastatic NSCLC who
have no other treatment option
with a median duration of response
of 7.4 months.
The approval is part of the FDA’s
Breakthrough Therapy designation.The above article was sent to subscribers in Pharmacy Daily's issue from 01 May 14 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 01 May 14
DEMENTIA Australia has appointed comedian Geraldine Hickey (pictured) as its newest Ambassador, coinciding with the Melbourne Memory Walk & Jog event taking place this Sun.
NEW research from the Monash Addiction Research Centre has highlighted a critical shortfall in the availability of Naloxone, a life-saving medication that reverses opioid overdoses, across community pharmacies in Australia’s most populous states.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.